Dataset from A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy

This phase 4, single-arm, open-label, multicenter study is designed to evaluate the efficacy
and safety of brentuximab vedotin as a single agent in adult participants with histologically
confirmed CD30+ relapsed or refractory classical Hodgkin Lymphoma who have not received a
prior stem cell transplantation (SCT) and are considered to be not suitable for SCT or
multiagent chemotherapy at the time of study entry.